Myozyme (Alglucosidase Alfa)

Alglucosidase alfa, the active ingredient in Myozyme, is an enzyme replacement therapy presented as a 20 mg per vial (5 mg/mL) lyophilized powder for solution for injection for intravenous use. It replaces the deficient acid alpha‑glucosidase enzyme in patients with Pompe disease (acid alpha‑glucosidase deficiency).

GNH USA supplies Myozyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Myozyme is used in the management of Pompe disease, a lysosomal storage disorder caused by acid alpha‑glucosidase deficiency.

- Infantile‑onset Pompe disease: improves survival and motor development. - Late‑onset Pompe disease: stabilizes respiratory function and muscle strength. - Adult Pompe disease: reduces disease progression and supports daily activities.

Myozyme may be associated with infusion‑related reactions and other adverse events.

Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Nausea: mild to moderate sensation of stomach upset. - Headache: occasional mild headache following administration. - Rash: localized skin redness or itching at the infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: sudden drop in blood pressure during infusion. - Cardiac arrhythmia: irregular heart rhythm observed in some patients. - Pulmonary edema: fluid accumulation in the lungs presenting with breathing difficulty.

Before initiating Myozyme therapy, several precautions should be considered to ensure patient safety.

- Renal function: assess baseline kidney status and monitor during treatment. - Cardiac status: evaluate heart function because patients may have underlying cardiomyopathy. - Infusion rate: start at a slow rate and adjust to minimize infusion reactions. - Immunogenicity: monitor for development of anti‑drug antibodies that could reduce efficacy. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Myozyme can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Concomitant lysosomal enzyme therapies: may increase immunogenic risk. - Live vaccines: may have reduced effectiveness due to immune modulation.

Moderate Interactions (Monitor Closely): - Antihistamines: can mask early signs of infusion reactions. - Corticosteroids: may alter immune response and affect antibody formation. - Other intravenous biologics: schedule to avoid overlapping infusion times.